Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.55 HKD | +0.38% | -2.57% | -32.10% |
May. 29 | JD.com's Healthcare Arm Shuttering Family Doctor Initiative | MT |
May. 29 | China stocks close marginally higher after IMF upgrades GDP forecasts | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 55% by 2026.
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 1.05 for the current period. Therefore, the company is undervalued.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- With an expected P/E ratio at 35 and 27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.10% | 10.8B | B | ||
-10.85% | 7.31B | B | ||
+9.89% | 6.19B | C | ||
-11.53% | 5.89B | C+ | ||
+73.65% | 4.79B | C | ||
-4.09% | 4.58B | D- | ||
-8.36% | 3.75B | B | ||
-20.92% | 3.14B | C- | ||
-13.87% | 2.82B | C- | ||
-10.94% | 2.57B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6618 Stock
- Ratings JD Health International Inc.